GATC Health’s Derisq Named One of The Scientist’s 2026 Top Innovations

GATC’s Derisq™, the definitive AI report for predictive risk intelligence, named a Top Emerging Startup Technology by independent panel of life sciences experts at the esteemed publication.

September 29, 2026 — GATC Health Corp (“GATC”), a tech-bio company applying artificial intelligence and multiomics to de-risk and accelerate drug discovery and development, today announced that its Derisq™ AI report has been named one of The Scientist’s 2026 Top Innovations, recognizing technologies poised to advance life sciences research, biotechnology and healthcare. Read by 330,000 subscribers and garnering 7.1 million pageviews annually, The Scientist has been a trusted resource for industry professionals for 40 years.

Derisq was selected as one of three winners in the Emerging Startup Technologies category, which recognizes new technologies with the potential to disrupt the market. Derisq was among just 10 technologies recognized across four categories, following evaluation by an independent panel of scientists and life sciences experts with no financial ties to the products or companies considered. 

“It means a lot that independent scientists looked at Derisq and saw what we see in it. That’s a tough audience for an AI claim,” said Jayson Uffens, Chief Technology Officer, Co-Founder and Chairman of GATC Health. “Drug development has always asked biotech leaders and investors to make expensive decisions on incomplete information. What can change is when they get it. Derisq puts a read on efficacy, safety and clinical risk in front of them earlier, before the money moves. That’s the job it was built to do.”

Powered by GATC Health’s proprietary Operon® AI platform, Derisq uses in silico modeling to evaluate drug candidates and generate prospective insights into safety, efficacy, off-target effects and potential clinical outcomes. The platform is designed to support biotech executives, pharmaceutical companies, investors and other stakeholders making high-stakes decisions about asset development, trial design and capital allocation.

Derisq’s underlying technology has been independently evaluated by the University of California, Irvine, demonstrating 91% specificity in identifying off-target risks and 86% sensitivity in predicting target activation. GATC’s technology is currently being used across biopharma, investment and insurance applications to provide additional predictive intelligence before and during clinical development.

The Scientist’s Top Innovations competition, established in 2008, annually recognizes technologies and products advancing life sciences research and healthcare. Winners of the 2026 competition span four categories: Biotechnology, Lab Research Tools, Healthcare and Diagnostics, and Emerging Startup Technologies.

For more information about Derisq, visit GATC Health’s website.